Background
==========

Colon cancer is the third most common cancer in the western world, and surgery is the only curative treatment. Approximately one-third of those resected will experience recurrent disease with an expected survival of less than two years \[[@B1]\]. Most patients treated with curative intent are included in some form of surveillance program involving periodic evaluations to detect asymptomatic recurrence. Reviews comparing various surveillance programs have suggested that more intensive surveillance strategies tend to increase five-year overall survival by 5-10% \[[@B2],[@B3]\].

However, all preventive programs have associated costs and risks \[[@B4]-[@B7]\]. The survival benefits of a surveillance program for colon cancer survivors are well known, but much less is known about the potential negative impacts for patients and their loved ones \[[@B3]\]. False positive test results may negatively impact quality of life (QoL) by leading patients and family members to believe that recurrence has occurred. On the other hand, false negative tests may result in diagnostic delay during which a potentially curable recurrent cancer may become inoperable. In order to more rationally weigh benefits and harms of post-operative surveillance programs, patients and providers need information to help them better understand the implications of positive and negative test results \[[@B6]\]. In addition, it is important to understand the resource use associated with work-up of suspected recurrence and the benefit which can be expected in terms of opportunities for curative treatment of recurrence.

Previously, we have reported the cost-effectiveness and QoL results from a Norwegian randomized trial comparing general practitioner (GP) versus surgeon-organised colon cancer surveillance according to national guidelines \[[@B8],[@B9]\]. In this work, we focus on the outcomes of individuals who underwent a diagnostic work-up in response to a positive surveillance test result or development of interval symptoms that raised concern for recurrence. These outcomes include whether the initial positive test results or symptoms represented a false positive or whether they served as the first sign of a true recurrence, as well as subsequent resource use for both true and false positives. Among patients with true positive tests or symptoms, we examine the extent to which curative resection of recurrent disease was possible.

Methods
=======

Data from a randomised trial assessing a colon cancer surveillance program based on Norwegian National Guidelines (ClinicalTrials.gov identifier NCT00572143), was linked to follow-up data from the electronic medical records (EMRs) of four Norwegian hospitals \[[@B8],[@B9]\]. Patients who underwent a diagnostic work-up as a result of a positive surveillance test or symptoms suggesting possible recurrence were identified, and subsequent health care resource utilization was quantified. Patients were enrolled in the surveillance program between June 1, 2007 and December 15, 2011.

Outcomes
--------

Primary outcomes included 1) Positive predictive value and false positive rates for initial positive surveillance test results or symptoms suggestive of possible recurrence, 2) subsequent resource use for patients with both true and false positives, and 3) whether curative resection of recurrent disease was possible. Secondary outcomes included time from initial detection to confirmation of recurrence, number needed to test per curative resection of recurrence, and cost per curative resection of recurrence.

Ethics
------

The Regional Committee for Medical Research Ethics (P REK NORD 79/ 2006) and the Norwegian Data Inspectorate approved the research protocol; all patients provided informed written consent.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were age less than 75 years with recent curative surgery for Dukes' stage A, B or C colon cancer. Patients receiving postsurgical adjuvant chemotherapy (some Dukes' B and all Dukes' C) were eligible to participate. Exclusion criteria were age greater than 75 years, membership in a healthcare trust not participating in the trial, inability to provide informed consent, and Dukes' stage D cancer. Patients were followed for up to 2 years (Table [1](#T1){ref-type="table"}).

###### 

Norwegian Gastrointestinal Cancer Group (NGICG) 2007 Surveillance Program

  **Examination/test**     **Surveillance cycle (postoperative months)**                                                      
  ----------------------- ----------------------------------------------- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
  Chest x-ray                                                                  X       X       X       X       X       X       X
  Liver ultrasonography                                                        X       X       X       X       X       X       X
  Colonoscopy                                                                          X                               X        
  CEA measurement                                X                         X   X   X   X   X   X   X   X   X   X   X   X   X   X
  Clinical examination                           X                         X   X   X   X   X   X   X   X   X   X   X   X   X   X

Description of the surveillance program
---------------------------------------

The GP- and surgeon-followed arms underwent the same surveillance regimens based on Norwegian Gastrointestinal Cancer Group 2007 surveillance guidelines (Table [1](#T1){ref-type="table"}). The surveillance period included in analyses included nine surveillance cycles (one month through 24 months postoperatively) with regular clinical examinations, CEA measurement, chest x-ray, contrast-enhanced liver ultrasound and colonoscopy according to the intervals described in Table [1](#T1){ref-type="table"}.

Hospitals, primary and secondary care professionals
---------------------------------------------------

Three local hospitals and one university hospital trust participated. Approximately 100 patients with colon cancer are surgically treated annually at these four hospitals. Approximately 550 GPs work in the health care trust.

Serious clinical events
-----------------------

A serious clinical event (SCE) was defined as an episode leading to suspicion of cancer recurrence. An SCE could be triggered by the reported symptoms (at routine consultation or in the intervals between surveillance visits), the clinical findings at surveillance visits or the findings of surveillance tests. The symptoms and clinical findings initiating a diagnostic check-up could include the following: lesion suspicious for colorectal cancer at colonoscopy or rectal examination; increased carcinoembryonic antigen (CEA) values revealed by repeated measurements; blood in the stool detected by the Hemofec (fecal occult blood) test; unexplained abdominal pain; unexplained weight loss of 5 kg during the previous three months; palpable lymphadenopathy; possible metastatic lesions on chest x-ray, liver ultrasound or CT scan; or other signs or symptoms suggestive of cancer recurrence. The time to recurrent cancer diagnosis was defined as the time from an SCE (dated in the GP referral or hospital electronic medical record \[EMR\]) until the completion of the ensuing diagnostic work-up.

Data collection
---------------

Data on radiology tests, colonoscopies, blood tests, surgical consultations, surgeries, pathology studies, admissions, and hospital discharges were abstracted from the EMRs of all included patients and were used to identify SCEs. In the case of missing information, the surgeons, GPs, or patients were interviewed by telephone. False positive SCEs were considered to have occurred when an SCE triggered a subsequent diagnostic work-up that ruled out recurrence. We identified successful R0 resections of recurrent local or metastatic disease by examining the surgical and postoperative pathology reports.

Statistics
----------

Proportions were compared using 2x2 contingency tables, and Chi Squared or Fisher's exact tests with an alpha level of 0.05. Continuous values were compared using t-tests with a two-sided alpha value of 0.05. The results were expressed using the mean differences for continuous outcomes with the corresponding standard deviations (SD), 95% confidence intervals (CI), and associated p-values. P-values were reported to three decimal places, and p-values less than 0.001 were reported as p \< 0.001. The surveillance program's positive predictive value was defined as the proportion of SCEs that were true positives (i.e., true cancer recurrences).

The economic evaluation of cost per R0 resection was performed from a societal perspective. Cost elements were converted into British pounds (BP £) at a rate of BP £ = 9.39 Norwegian krone (NOK) (<http://www.norges-bank.no>). Unit costs assigned to health care resources have been previously reported \[[@B8]\]. To address the uncertainty aspect of the cost per R0 metastases resections, we performed a many-inputs/one-output sensitivity analyses, with results expressed in a Tornado chart. All analyses were performed using IBM SPSS Statistics v 19.0 (IBM Company SPSS 2010) and Microsoft Excel for Mac 2011.

Results
=======

A total of 110 patients surgically treated for colon cancer met the inclusion criteria and were enrolled in the randomised trial. Fifty-five were followed by their GPs and 55 were followed in a surgical outpatient department. Overall, 85 patients (75%; GP 41 vs. surgeon 44) were followed for at least 12 months, and 58 patients (52%; GP 29 vs. surgeon 29) were followed for 24 months. The total surveillance time was 1884 person-months; median follow up time was 17 months. Overall, 1105 tests (colonoscopy n = 115, liver ultrasound n = 209, chest x-ray n = 278, carcinoembryonic antigen n = 503) were performed and 1186 consultations occurred (Table [2](#T2){ref-type="table"}).

###### 

Demographics of the patients enrolled in a National CRC Surveillance Program

  **Variable**                        **Surgeon-surveillance n = 55 (%)**   **GP-surveillance n = 55 (%)**   **Total n = 110 (%)**   **p value**
  ---------------------------------- ------------------------------------- -------------------------------- ----------------------- -------------
  Mean age (SD)                                   66.7 (7.3)                          64.0 (8.7)                  65.4 (8.1)             ns
  Male                                             32 (58.2)                          33 (60.0)                    65 (59.1)             ns
  Female                                           23 (41.8)                          22 (40.0)                    45 (40.9)             ns
  **Tumour location**                                                                                                               
  Coecum                                           13 (23.6)                          13 (23.6)                    26 (23.6)             ns
  Ascendens                                        9 (16.3)                            5 (9.1)                     14 (12.7)             ns
  Transversum                                       4 (7.2)                            5 (9.1)                      9 (8.1)              ns
  Decendens                                         1 (1.8)                            4 (1.8)                      5 (4.5)              ns
  Sigmoid                                          28 (50.9)                          28 (50.9)                    56 (50.9)             ns
  **Type of surgery**                                                                                                               
  Laparoscopic                                     14 (25.5)                          11 (20.0)                    25 (22.7)             ns
  Open                                             41 (74.5)                          44 (80.0)                    85 (77.3)             ns
  **Tumour stage**                                                                                                                  
  Dukes A                                          12 (21.8)                          11 (20.0)                    24 (21.8)             ns
  Dukes B                                          25 (45.5)                          30 (54.5)                    55 (50.0)             ns
  Dukes C                                          18 (32.7)                          14 (25.5)                    32 (29.0)             ns
  Total surveillance months                           942                                942                         1884                ns
  Median surveillance (months)                        17                                  17                          17                 NA
  **Surveillance tests n**                            513                                592                         1105                ns
  Carcinoembryonic antigen CEA (%)                 203 (39)                            300 (51)                       503              \<0.001
  Chest X-ray (%)                                  150 (29)                            128 (21)                       278               0.003
  Liver ultrasound (%)                             110 (21)                            99 (17)                        209               0.03
  Colonoscopy (%)                                   50 (9)                             65 (11)                        115                ns
  Consultations n                                     508                                678                         1186                ns

Serious clinical events and false positive tests
------------------------------------------------

A total of 48 SCEs were identified; 31 (65%) were initiated by emerging symptoms and 17 (35%) were initiated by test findings. Abdominal pain (n = 14, 29%) and blood in the stool (n = 10, 20%) were the most common presenting complaints. There were no significant differences between surgeons or GPs in terms of SCE occurrence or the time to diagnosis (Table [3](#T3){ref-type="table"}). Overall, 34 patients (30% of all trial patients) experienced a false positive event. The positive predictive value (i.e., the probability of a surveillance-initiated SCE being confirmed as true colon cancer recurrence) was 29% (surgeons 36% vs. GPs 23%).

###### 

Serious clinical events with suspicion of cancer recurrence

  **Serious clinical event characteristics**        **Surgeon-surveillance**   **GP-surveillance**   **Total**   **p value**
  ------------------------------------------------ -------------------------- --------------------- ----------- -------------
  Surveillance (months)                                       942                      942             1884          ns
  Interval SCE                                                 12                      13               25           ns
  Routine SCE                                                  11                      12               23           ns
  Total SCE                                                    22                      26               48           ns
  **Symptom initiated SCE**                                                                                     
  Abdominal pain (n)                                           3                       11               14          0.05
  Blood in stool (n)                                           6                        4               10           ns
  Anaemia (n)                                                  0                        1                1           ns
  Weight loss (n)                                              1                        1                2           ns
  Lymphadenopathy (n)                                          2                        0                2           ns
  Other findings (n)                                           1                        1                2           ns
  Total                                                        13                      18               31           ns
  True cancer recurrence                                       4                        3                7           ns
  **Test initiated SCE**                                                                                        
  Elevated CEA                                                 2                        4                6           ns
  Radiology                                                    6                        3                9           ns
  Colonoscopy                                                  1                        1                2           ns
  Total                                                        9                        8               17           ns
  True cancer recurrence                                       4                        3                7           ns
  False positive tests and symptoms (%)                     14 (25%)                20 (36%)         34 (31%)        ns
  Program positive predictive value                           0.36                    0.23             0.29          ns
  **Diagnostics for potential recurrent cancer**                                                                
  CEA (repeated)                                               2                        4                7           ns
  Chest x-ray                                                  4                        3                6           ns
  CEUS                                                         2                        6                6           ns
  Colonoscopy                                                  3                       12               15          0.05
  CT thorax/abdomen/liver                                      13                       8               21           ns
  PET                                                          0                        2                2           ns
  Consultations                                                14                      23               37           ns
  Diagnostic work-up days (SD)                              45 (45)                  35 (28)          39 (35)        ns

PPV: positive predictive value, which is the proportion of positive test/clinical findings that are true positives (i.e., true cancer recurrences). ns: not significant.

Clinical presentation of colon cancer recurrence
------------------------------------------------

Of the 48 patients with SCEs, 14 (29%) had colon cancer recurrence. Symptoms were the most common initial indication of recurrence (n = 7), followed by radiologically detected lesions (n = 4) and elevated CEA levels (n = 3) (Table [4](#T4){ref-type="table"}).

###### 

Clinical presentation of colon cancer recurrence

  **Case no**                **Gender**   **Presenting problem**                                                                **Routine vs. interval**   **Diagnostic tests**   **Metastatic site**               **Time to diagnosis (days)**   **Metastasis surgery**   **Time to surgery (days)**
  -------------------------- ------------ ------------------------------------------------------------------------------------- -------------------------- ---------------------- --------------------------------- ------------------------------ ------------------------ ----------------------------
  **GP-surveillance**                                                                                                                                                                                                                                                       
  1                          F            Elevated CEA                                                                          Routine                    CEUS                   Disseminated                      27                             No                       Inoperable
  PET CT                                                                                                                                                                                                                                                                    
  2                          M            Abdominal pain                                                                        Interval                   CEUS                   Liver                             21                             No                       Inoperable
  3                          M            Elevated CEA                                                                          Routine                    CEA                    Disseminated                      71                             No                       Inoperable
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  4                          M            Metastatic lesion detected at CEUS                                                    Routine                    CEUS                   Liver                             4                              Yes                      38
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  5                          F            Abdominal pain, normal CEA, CT and CEUS, disseminated cancer detected at laparotomy   Interval                   CEUS                   Disseminated                      270                            Yes                      270
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  6                          M            Abdominal tenderness                                                                  Interval                   Anorectoscopy          Local recurrence                  2                              Yes                      30
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  **Surgeon-Surveillance**                                                                                                                                                                                                                                                  
  7                          M            Metastatic lesion detected chest x-ray                                                Routine                    CT thorax              Lung                              45                             Yes                      62
  CT abdomen                                                                                                                                                                                                                                                                
  8                          M            Stoma bleeding                                                                        Interval                   Colonoscopy            Local and lymph node recurrence   10                             No                       Inoperable
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  9                          M            Weight loss                                                                           Routine                    CT Thorax              Lung                              45                             No                       Inoperable
  Night sweating             CT abdomen                                                                                                                                                                                                                                     
  10                         M            Metastatic lesion detected at chest-x ray                                             Routine                    CT Thorax              Lung                              4                              Yes                      42
  CT abdomen                                                                                                                                                                                                                                                                
  11                         M            Metastatic lesion detected on CEUS                                                    Routine                    MR liver               Liver                             3                              Yes                      43
  CT thorax                                                                                                                                                                                                                                                                 
  CT abdomen                                                                                                                                                                                                                                                                
  12                         F            Abdominal pain                                                                        Interval                   CT abdomen             Disseminated                      16                             No                       Inoperable
  CT thorax                                                                                                                                                                                                                                                                 
  13                         M            Elevated CEA                                                                          Routine                    CT thorax              Liver                             30                             No                       Inoperable
  CT abdomen                 Lung                                                                                                                                                                                                                                           
  CT liver                                                                                                                                                                                                                                                                  
  14                         F            Occult blood in faeces                                                                Interval                   CT thorax              Liver                             31                             Yes                      35
  CT abdomen                                                                                                                                                                                                                                                                
                                                                                                                                                           CEUS                                                                                                              

Harms and benefits of cancer surveillance
-----------------------------------------

In this surveillance program, 14 recurrences were detected, seven subsequent surgeries were performed, and four R0 resections of metastases were achieved by surveilling 110 patients over a total of 1884 months. This means that 276 tests and 296 healthcare consultations were needed per R0 resection; the cost per R0 resection was £ 103207.

A 25% increase in successful R0 metastases surgeries decreased the cost per surgery to £ 82566 (sensitivity analyses Figure [1](#F1){ref-type="fig"}). Three patients had asymptomatic but incurable recurrences. Mean time from SCE to confirmation of recurrence was 39 days (standard deviation 35 days). The mean quality of life was equal to that of the general UK population (Table [5](#T5){ref-type="table"}) \[[@B10]\].

![**A sensitivity analysis varying the major cost factors.** The base case per R0 resection was set as origo (£103,000). Variance in the number of successful R0 metastases resections has a major impact on overall cost (range £ 82,566 to £ 123, 847).](1472-6963-14-137-1){#F1}

###### 

Fact box of the side-effects and benefits of CRC surveillance

  **Variable**                                                                                                **Surveillance effects**
  ------------------------------------------------------------------------------------------------------ -----------------------------------
  ***Resource use***                                                                                     
  Analysed surveillance months                                                                              110 patients for 1884 months
  Cost per successful R0 resection (£)                                                                                 103207
  **Screening tests per R0 metastases resection**                                                        
  Carcinoembryonic antigen CEA (n)                                                                                       125
  Chest x-ray (n)                                                                                                        70
  Liver ultrasound (n)                                                                                                   52
  Colonoscopies (n)                                                                                                      30
  Total screening tests (n)                                                                                              276
  Total health care consultations (n)                                                                                    296
  ***Benefits***                                                                                         
  Number of cancer recurrences detected (n)                                                                              14
  Probability of R0 metastasis surgery (%)\*                                                              57% (4 of 7 metastasis surgeries)
  ***Side effects***                                                                                                       
  False positive events (n)                                                                                           34 (31%)
  Probability of recurrent cancer when diagnostic check up i.e. surveillance positive predictive value                   29%
  ^*a*^Mean days to SCE diagnosis (SD)                                                                                 39 (35)
  Asymptomatic but incurable metastases recurrences                                                           3 of 14 recurrences (21%)
  ***Quality of life***                                                                                  
  ^a^Mean EQ-5D VAS score (CI)                                                                                    75.9 (74.5-77.3)
  ^a^Mean EQ-5D Index score (CI)                                                                                  0.862 (0.84-0.87)

\*R0 surgery is defined as positive histological resection margins. ^a^Reported in a previous publication \[[@B8]\]. Equals that of the general UK population \[[@B10]\].

Discussion
==========

Summary of findings
-------------------

A representative population of patients surgically treated for colon cancer was enrolled in a colon cancer surveillance program based on Norwegian national guidelines, with an expected normal variance of demographic factors and colon cancer severity. The patients were followed for up to two years (i.e., the period during which most cancer recurrences manifest). Thirty percent (34 of 110) of all the surveillance patients experienced false positive tests, and the probability of having a cancer recurrence when a diagnostic check-up was initiated was 29%. Overall, 276 tests were needed to save one patient from recurrent colon cancer, and the total cost per successful surgery for recurrence was £ 103207.

Comparison of existing literature
---------------------------------

The potential negative side effects (physical and psychological) and costs of cancer surveillance strategies have not been well delineated \[[@B4]-[@B7]\]. None of the studies included in the previous reviews of colorectal cancer surveillance have provided any specific details of the harms (mortality or morbidity) resulting from investigating or treating recurrences \[[@B2],[@B3]\]. However, a potential harm from any secondary prevention program is well recognised to be over-diagnosis and false positive tests \[[@B7],[@B11]\].

Some researchers have investigated the psychological effects of colorectal cancer surveillance \[[@B8],[@B12],[@B13]\]. None of these studies have found deterioration in the patient QoL with surveillance. Nevertheless, in recent meta-analyses, it was shown that anxiety, rather than depression, was a major problem among long-term cancer survivors. It is unknown, however, what impact a cancer surveillance program itself has on anxiety levels \[[@B14]\].

The challenge of postoperative cancer surveillance is that a vast majority of patients must undergo a large number of tests without any benefit, or even with some potential harm, to identify a few patients with curable recurrence. The high rate of false positive tests (n = 34, 30% of all surveillance patients) in this trial was more than we expected and likely negatively impacts the patient's and family's QoL. False positive and true positive tests in colorectal cancer surveillance have been addressed in previous reviews \[[@B15]\]. According to Kievit et al., 370 positive surveillance tests (26 true positives, 7%) and 11 surgeries were required to provide one patient with a long-term survival benefit (five years) \[[@B15]\]. In our survey, 1186 tests were performed during the 1884 person-month surveillance period, which equals 276 tests per successful R0 metastasis surgery. This finding aligned with the results from another Norwegian survey, which reported 270 tests per successful R0 resection \[[@B16]\]. The estimated cost of £ 103207 per successful R0 metastases resection is higher than reported by other authors. Kørner et al. reported an estimated cost per R0 resection of £ 15278 (US \$ 25289),

Identification of asymptomatic but incurable recurrent disease through surveillance testing raises ethical and quality of life considerations \[[@B5],[@B17]\]. In our study, three patients (21%, Table [4](#T4){ref-type="table"}) had asymptomatic but incurable colon cancer recurrence. These figures are somewhat higher than those in a previous study reporting 9% asymptomatic but incurable disease detected in a surveillance program \[[@B16]\].

The imperfect nature of specific surveillance tests themselves (i.e., test sensitivity and specificity) can contribute to the potential harms of surveillance. National surveillance programs are often based on serial CEA measurements, and this biomarker has several pitfalls and shortcomings. A recent study showed that the diagnostic accuracy of serial CEA measurements is low and is impacted by the cut-off value used \[[@B18]\]. Similarly, radiological tests have varying sensitivity and specificity, the latter of which impacts the rate of false positive tests. For example, the rate of false positive tests in CT chest scans has been reported to be as high as 30-50%; as a result, this test is not recommended by some physicians for post-treatment surveillance purposes \[[@B19]\].

Studies of secondary prevention practices around other cancer types have explored potential harmful effects of these programs. In a systematic review addressing screening for lung cancer using thoracic CT scans, most of the detected lung nodules (\> 90%) were benign, and invasive nonsurgical procedures in patients with benign lesions were common \[[@B20]\]. Forty-six percent of patients reported psychological distress while awaiting the confirmation of a potential cancer diagnosis \[[@B21]\]. Thus, the potential harms of a preventive program must be carefully weighed against any benefits \[[@B20]-[@B22]\]. In the case of colonoscopic colorectal cancer surveillance, the potential harms of the procedure (including significant discomfort, bleeding, and perforation) coupled with the low rate of intraluminal cancer recurrence, have led some to debate whether colonoscopy should be routinely included in surveillance programs \[[@B23]\].

Strengths and limitations
-------------------------

This study has some strength. It represents the first trial to analyse the potential side effects of colon cancer surveillance, an area of considerable uncertainty. Jeffery and Hider outlined this uncertainty around side effects of colorectal cancer surveillance in their 2007 Cochrane review \[[@B3]\]. This study has limitations. The trial was designed to assess whether general practice surveillance affected patient-specific QoL and cost-effectiveness compared to surgeon-led surveillance \[[@B9]\]. A trial assessing survival would require a larger sample size and a longer surveillance time. We acknowledge that this choice of a follow-up period might have impacted the observed frequency of SCE and thus of recurrence. Thirteen percent (n = 14) of trial patients had colon cancer recurrence; this low recurrence rate was most likely related, at least partly, to the short follow-up duration (median 17 months). Therefore, our calculation of the cost per successful R0 recurrence surgery might represent an overestimate. To address this uncertainty, we performed a sensitivity analysis in which we estimated the cost per R0 resection if a 25% increase in successful resections was observed (Figure [1](#F1){ref-type="fig"}). However, in our opinion, the analysed time period gives a realistic overview of the magnitude and rate of side effects in a colon cancer surveillance program.

Conclusion
==========

Information on a range of outcomes should be available to fully assess the net benefit or harm of colon cancer surveillance. Any survival benefit of the surveillance must be balanced against the potential harms inherent to ensure that surveillance programs are acceptable. Providers are best positioned to inform patients and their families of these benefits and potential harms. The nature of postoperative cancer surveillance is that a vast majority of patients (96% in the present study) must undergo a large number of tests without any benefit, or even with some harm to themselves and their family, to identify a few patients with curable recurrence. Patients with asymptomatic but incurable disease (21% of all recurrences in the present study) likely represent the most controversial group and raise ethical and quality of life considerations \[[@B16]\]. The reported cost of £ 103207 per R0 resection of recurrent disease is significantly higher than that reported by others \[[@B16]\].

In conclusion, due to the high rate of false positive tests and low positive predictive value of the surveillance program examined, we feel that a more tailored surveillance approach based on recurrence risk and likely recurrence pattern is needed in future CRC surveillance programs. Such an approach has the potential to reduce costs and the number of false positive tests, while improving positive predictive value. There is nothing in the current evidence base suggesting that such an approach will compromise the potential survival benefit of CRC surveillance. In addition, further research is needed regarding the potential harms of colorectal cancer surveillance, including quality of life impacts due to false positive surveillance tests and to early diagnosis of incurable recurrence. The estimated cost of surveillance is considerable, and whether the identified costs are acceptable when comparing the benefits and harms is a matter of discussion not only among policy and decision makers, but also among providers, patients, and families.
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